Guggenheim Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $1.75

Adaptimmune Therapeutics (NASDAQ:ADAP) had its target price dropped by equities researchers at Guggenheim from $3.00 to $1.75 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock.

ADAP has been the topic of a number of other research reports. Scotiabank lowered their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research report on Friday, March 21st. Mizuho dropped their price target on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. StockNews.com started coverage on Adaptimmune Therapeutics in a report on Friday, March 21st. They issued a “buy” rating for the company. Finally, Wells Fargo & Company lowered their target price on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a report on Friday, March 21st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1.93.

Adaptimmune Therapeutics Stock Down 4.4 %

ADAP stock opened at $0.22 on Wednesday. The stock has a market capitalization of $56.29 million, a P/E ratio of -1.00 and a beta of 2.52. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics has a 1-year low of $0.22 and a 1-year high of $1.65. The business has a fifty day moving average price of $0.51 and a 200-day moving average price of $0.68.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The business had revenue of $3.22 million during the quarter, compared to analysts’ expectations of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. Equities analysts forecast that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Two Seas Capital LP purchased a new stake in Adaptimmune Therapeutics in the fourth quarter worth about $7,992,000. Two Sigma Investments LP grew its stake in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 19,146 shares during the period. Two Sigma Advisers LP increased its holdings in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 58,787 shares in the last quarter. Jane Street Group LLC raised its stake in Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 152,780 shares during the period. Finally, Long Focus Capital Management LLC lifted its holdings in Adaptimmune Therapeutics by 54.1% during the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock valued at $11,040,000 after purchasing an additional 7,194,503 shares in the last quarter. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.